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Paraganglioma-associated takotsubo cardiomyopathy has not been 
widely reported. This case underscores the strong association 
between excess sympathetic stimulation and takotsubo 
contractile pattern. 
 •  Hypertension, headache, and diaphoresis suggest an early 
functional tumor. However, takotsubo cardiomyopathy and 
cardiogenic shock may occur late in an asymptomatic patient.
 •  If malignant paragangliomas are diagnosed, a baseline 
cardiovascular evaluation should be initiated, which should 
include electrocardiogram and echocardiogram in case subsequent 
cardiovascular collapse occurs. 
 •  Patients with paragangliomas should undergo genetic testing 
to identify mutations associated with malignancy, most notably 
succinate dehydrogenase type B mutations. If malignant-associated 
mutations exist, close follow-up.
 •  Catecholamine secreting tumors should be kept high on the 
differential if a patient presents with takotsubo cardiomyopathy in 
the absence of an obvious trigger.
Case Presentation Discussion
Figure 1. Sagittal view and coronal view of thoracic and lumbar spines, 
showing left paravertebral mass at T7-T10 (encircled).
Figure 2. Coronal view, octreotide scan: White arrow consistent with an 
octreotide avid tumor left-sided paraspinous mass at the T9-T10 level.
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The WHO: Paragangliomas, uncommon 
catecholamine-producing tumors arising from 
extra-adrenal chromaffin cells. Catecholamines 
released from the tumor stimulate both alpha- 
and beta-adrenergic receptors.
The WHERE: Pheochromocytomas arise 
in the adrenal medulla. However, when 
catecholamine-producing tumors occur in extra-
adrenal sympathetic ganglia, they are called 
paragangliomas. They may occur sporadically or 
as part of a hereditary syndrome (i.e. MEN2, von-
Hippel Lindau syndrome).
The HOW: About 10% of paragangliomas are 
malignant often arising in the setting of germline 
mutations in a mitochondrial complex subunit- 
succinate dehydrogenase (SDH).
The WHAT: Malignant catecholamine 
stimulation can result in catastrophic 
effects including a stress cardiomyopathy 
(takotsubo cardiomyopathy), characterized 
by left ventricular dysfunction and potential 
cardiovascular collapse.
The WHY: Catecholamine-secreting tumors 
should be included in the differential diagnosis of 
takotsubo cardiomyopathy if other causes have 
been ruled out. If metastatic paragangliomas are 
found, genetic testing is warranted to seek out 
mutations, especially SDHB.
A 54 year-old male presented with unexplained chest pain. An exercise stress test elicited frequent PVCs, 
ventricular tachycardia, and idioventricular rhythms. A subsequent cardiac catheterization showed mild luminal 
irregularities of coronaries; however, a left ventriculogram showed ejection fraction of 35% with evidence of 
apical ballooning consistent with a takotsubo cardiomyopathy. An evaluation coincidentally identified para-aortic 
and retroperitoneal masses. Circulating free catecholamines and 24-hour urinary metanephrines were elevated. 
He was diagnosed with a paraganglioma-like tumor. Following excision of his paragangliomas, LV size and 
function normalized. Beta blocker therapy was initiated with resolution of PVCs and improvement of symptoms. 
Molecular testing identified a succinate dehydrogenase type B mutation in the paraganglioma, a feature typically 
associated with malignancy.
Introduction
